Group 1 - The proposal involves Blackstone and TPG acquiring Hologic in a take-private deal valued at up to $18.3 billion [8] - Hologic's stockholders would receive $76 per share, with an additional potential $3 per share based on revenue goals for the breast health business in fiscal years 2026 and 2027, representing a 46% premium to the stock's closing price on May 23 [4][8] - The deal includes debt financing commitments from major banks and equity commitments from Blackstone and TPG, along with minority investments from the Abu Dhabi Investment Authority and GIC [5] Group 2 - Hologic's board has unanimously approved the acquisition, which is expected to close in the first half of 2026, pending shareholder and regulatory approval [8] - Analysts suggest that the offered price is fair and that other bidders are unlikely due to Hologic's slower revenue growth and potential antitrust issues in the U.S. mammography market [6]